NASDAQ : CTXR
Citius Pharmaceuticals, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.5231 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 14.36M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 14.36M |
| Enterprise Value | 4.53M |
Dates
| Measure | Value |
|---|
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 27.45M |
| Shares Outstanding | 27.45M |
| Shares Change (YoY) | +154.35% |
| Shares Change (QoQ) | +16.95% |
| Owned by Insiders (%) | 1.80% |
| Owned by Institutions (%) | 4.94% |
| Float | 26.96M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.02 |
| Forward PS | 0.81 |
| PB Ratio | 0.22 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | 0.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 0.84 |
| Quick Ratio | 0.34 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -82.51 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -81.09% |
| Return on Assets (ROA) | -26.57% |
| Return on Invested Capital (ROIC) | -47.02% |
| Return on Capital Employed (ROCE) | -63.32% |
| Weighted Average Cost of Capital (WACC) | 9.20% |
| Revenue Per Employee | $308,922 |
| Profits Per Employee | -$2.01M |
| Employee Count | 23 |
| Asset Turnover | 0.05 |
| Inventory Turnover | 0.08 |
Taxes
| Measure | Value |
|---|
| Income Tax | 189,923 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.04 |
| 52-Week Price Change | -65.36% |
| 50-Day Moving Average | 0.54 |
| 200-Day Moving Average | 0.66 |
| Relative Strength Index (RSI) | 54.10 |
| Average Volume (20 Days) | 274,206 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.70M |
| Short Previous Month | 5.59M |
| Short % of Shares Out | 20.76% |
| Short % of Float | 21.14% |
| Short Ratio (days to cover) | 30.78 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 7.11M |
| Gross Profit | 5.50M |
| Operating Income | -57.37M |
| Pretax Income | -57.98M |
| Net Income | -46.27M |
| EBITDA | n/a |
| EBIT | -57.37M |
| Loss Per Share | -$2.12 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 17.01M |
| Total Debt | 7.18M |
| Net Cash | 9.83M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 75.91M |
| Book Value Per Share | 2.43 |
| Working Capital | -8.32M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -34.87M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 127,693 |
| Net Borrowing | 8.64M |
| Free Cash Flow | -34.87M |
| FCF Per Share | -$1.27 |
Margins
| Measure | Value |
|---|
| Gross Margin | 77.34% |
| Operating Margin | -807.43% |
| Pretax Margin | -815.97% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -154.35% |
| Shareholder Yield | n/a |
| Earnings Yield | -405.64% |
| FCF Yield | -242.80% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Nov 26, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -3.9 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |